Clinical Trial Update: HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis [Phase 1]

View source ↗

Summary

A Phase 1 study of the HEPLISAV-B hepatitis B vaccine in adults with end-stage renal disease undergoing hemodialysis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• HEPLISAV-B (hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis) | Phase 1 | Status: COMPLETED | Results posted: 2024-08-09